Evidence map›Paper›PMID 35792044›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2023

Association of

Kaitlin A Quinn, Mark A Ahlman, Hugh D Alessi, Michael P LaValley, Tuhina Neogi, Jamie Marko, Elaine Novakovich, Peter C Grayson

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. New avenues in childhood vasculitis.Pediatric rheumatology online journal · 2025
    Review
  10. Association of PET vascular activity score with Takayasu's arteritis angiographic progression.European journal of nuclear medicine and molecular imaging · 2025
    Observational
  11. Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Advances in PET Imaging of the CXCR4 Receptor: [Seminars in nuclear medicine · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kaitlin A QuinnSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID 0000-0002-5794-194X
Mark A AhlmanClinical Center, Radiology and Imaging Sciences, NIH, Bethesda, Maryland.
Hugh D AlessiSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Michael P LaValleyDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
Tuhina NeogiDivision of Rheumatology, Boston University School of Medicine, Boston, Massachusetts.ORCID 0000-0002-9515-1711
Jamie MarkoClinical Center, Radiology and Imaging Sciences, NIH, Bethesda, Maryland.
Elaine NovakovichSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Peter C GraysonSystemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.ORCID 0000-0002-8269-9438
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USBoston University · USNational Institutes of Health Clinical Center · US

Funding

Clinical Support Services for the NIAMS Intramural Research ProgramZIDAR041180 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COLBERT, ROBERT · 2009 to 2025
$119.2M
Vasculitis and Translational MedicineZIAAR041204 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI GRAYSON, PETER · 2015 to 2025
$15.4M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI TUHINA NEOGI · 2019 to 2026
$6.9M
Intramural NIH HHS Z99 AR999999NIAMS NIH HHS P30 AR072571
6 · The paper itself

Abstract

objectiveTo assess whether vascular activity seen on

methodsPatients with LVV were recruited into a prospective cohort. All patients underwent magnetic resonance angiography or computed tomography angiography and FDG-PET imaging. Follow-up imaging using the same imaging modalities was obtained ≥6 months later per a standardized imaging protocol. Arterial damage, defined as stenosis, occlusion, or aneurysm, and corresponding FDG uptake were evaluated in 17 arterial territories. On follow-up, development of new lesions was recorded, and existing lesions were characterized as improved, worsened, or unchanged.

resultsA total of 1,091 arterial territories from 70 patients with LVV (38 patients with Takayasu arteritis, 32 patients with giant cell arteritis) were evaluated. Over a median 1.6 years of follow-up, new lesions developed only in 8 arterial territories in 5 patients with Takayasu arteritis. Arterial lesions improved in 16 territories and worsened in 6 territories. Most arterial territories that did not have vascular activity on FDG-PET scan at baseline had no angiographic change over the follow-up period (787 [99%] of 793). Few territories with baseline FDG-PET activity had angiographic change over time (24 [8%] of 298), but of the territories that developed angiographic change, 80% had FDG-PET activity at baseline. Within the same patient, an arterial territory with baseline FDG-PET activity had significantly increased risk for angiographic change compared to a paired arterial territory without FDG-PET activity (odds ratio 19.49 [95% confidence interval 2.44-156.02]; P < 0.01). Concomitant edema and wall thickening further increased risk for angiographic change.

conclusionDevelopment of angiographic change was infrequent in this cohort of patients with LVV. A lack of baseline FDG-PET activity was strongly associated with stable angiographic disease. In cases of angiographic progression, change was preceded by the presence of FDG-PET activity.

Indexed as

Giant Cell ArteritisTakayasu ArteritisFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID35792044
PMCPMC9797426
OpenAlexW4283829174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.